Loncastuximab  (Synonyms: RB4v1.2)

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CD19

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

930  [NCBI]

P15391

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.46 kDa

1875032-68-0

Liquid

Colorless to light yellow

[Loncastuximab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow Cytometry analysis of Raji cells labelling CD19 (red) with Loncastuximab (anti-CD19) (HY-P99711). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Zinzani PL, et al. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Jan;148(1):177-190.  [Content Brief]

  [2]. Hess B, et al. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 Dec 10;24(1):11.  [Content Brief]